Molecular detection of prostate cancer in urine by GSTP1 hypermethylation - PubMed (original) (raw)
Affiliations
- PMID: 11555585
Molecular detection of prostate cancer in urine by GSTP1 hypermethylation
P Cairns et al. Clin Cancer Res. 2001 Sep.
Abstract
Novel approaches for the early detection and management of prostate cancer are urgently needed. Clonal genetic alterations have been used as targets for the detection of neoplastic cells in bodily fluids from many cancer types. A similar strategy for molecular diagnosis of prostate cancer requires a common and/or early genetic alteration as a specific target for neoplastic prostate cells. Hypermethylation of regulatory sequences at the glutathione S-transferase pi (GSTP1) gene locus is found in the majority (>90%) of primary prostate carcinomas, but not in normal prostatic tissue or other normal tissues. We hypothesized that urine from prostate cancer patients might contain shed neoplastic cells or debris amenable to DNA analysis. Matched specimens of primary tumor, peripheral blood lymphocytes (normal control), and simple voided urine were collected from 28 patients with prostate cancer of a clinical stage amenable to cure. Genomic DNA was isolated from the samples, and the methylation status of GSTP1 was examined in a blinded manner using methylation-specific PCR. Decoding of the results revealed that 22 of 28 (79%) prostate tumors were positive for GSTP1 methylation. In 6 of 22 (27%) cases, the corresponding urine-sediment DNA was positive for GSTP1 methylation, indicating the presence of neoplastic DNA in the urine. Furthermore, there was no case where urine-sediment DNA harbored methylation when the corresponding tumor was negative. Although we only detected GSTP1 methylation in under one-third of voided urine samples, we have demonstrated that molecular diagnosis of prostate neoplasia in urine is feasible. Larger studies focusing on carcinoma size, location in the prostate, and urine collection techniques, as well as more sensitive technology, may lead to the useful application of GSTP1 hypermethylation in prostate cancer diagnosis and management.
Similar articles
- Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens.
Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Gonzalgo ML, et al. Clin Cancer Res. 2003 Jul;9(7):2673-7. Clin Cancer Res. 2003. PMID: 12855646 - Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids.
Goessl C, Krause H, Müller M, Heicappell R, Schrader M, Sachsinger J, Miller K. Goessl C, et al. Cancer Res. 2000 Nov 1;60(21):5941-5. Cancer Res. 2000. PMID: 11085508 - Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.
Lin X, Asgari K, Putzi MJ, Gage WR, Yu X, Cornblatt BS, Kumar A, Piantadosi S, DeWeese TL, De Marzo AM, Nelson WG. Lin X, et al. Cancer Res. 2001 Dec 15;61(24):8611-6. Cancer Res. 2001. PMID: 11751372 - GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.
Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. Nakayama M, et al. J Cell Biochem. 2004 Feb 15;91(3):540-52. doi: 10.1002/jcb.10740. J Cell Biochem. 2004. PMID: 14755684 Review. - Molecular detection of prostate cancer: a role for GSTP1 hypermethylation.
Henrique R, Jerónimo C. Henrique R, et al. Eur Urol. 2004 Nov;46(5):660-9; discussion 669. doi: 10.1016/j.eururo.2004.06.014. Eur Urol. 2004. PMID: 15474280 Review.
Cited by
- Promoter hypermethylation in prostate cancer.
Park JY. Park JY. Cancer Control. 2010 Oct;17(4):245-55. doi: 10.1177/107327481001700405. Cancer Control. 2010. PMID: 20861812 Free PMC article. Review. - Clinical utility of prostate carcinoma molecular diagnostic tests.
Shappell SB. Shappell SB. Rev Urol. 2008 Winter;10(1):44-69. Rev Urol. 2008. PMID: 18470278 Free PMC article. - Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S, Isserlin R, Van der Kwast T, Zlotta AR, Bader GD, Fleshner NE, Bapat B. Kamdar S, et al. Clin Epigenetics. 2019 Mar 27;11(1):54. doi: 10.1186/s13148-019-0651-z. Clin Epigenetics. 2019. PMID: 30917865 Free PMC article. - Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.
Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM. Gurel B, et al. Adv Anat Pathol. 2008 Nov;15(6):319-31. doi: 10.1097/PAP.0b013e31818a5c19. Adv Anat Pathol. 2008. PMID: 18948763 Free PMC article. Review. - Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review.
Liss MA, Leach RJ, Sanda MG, Semmes OJ. Liss MA, et al. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2454-2462. doi: 10.1158/1055-9965.EPI-20-1104. Epub 2020 Oct 22. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 33093161 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous